الفهرس 
Acknowledgment
World Health Organization Barriers to complianceOnly 14 pages are availabe for public view
 |  | from | 117 |  |  |
| | | from | 117 | | |
Abstract
Schizophrenia is a serious mental disorder in which the patient experiences distorted perception of reality and disturbances in thinking, behavior, emotions and motivation (Atadokht et al., 2019). It is can be regarded as a “burden on the quality of life”. In recent years, quality of life (QoL) has become a central outcome criterion in research on severe mental illness (Karow et al., 2014). In particular, during long-term therapies subjective perception of general wellness and quality of life are clear factors influencing and maintaining adherence to treatment. Consequently, a significant role has been assigned recently to the notion of subjective well-being and quality of life even in patients submitted to psychotropic medications (Niolu et al., 2015). .
Significance of the study:
Schizophrenia is the fourth leading cause of disability in the developed countries, imposing enormous burdens on the patients, families and society (Yin et al., 2017). A review of the literatures reported that compliance rates were from 60 to 85% in schizophrenic patients during the first month of treatment, with only 50% at 6 months (Sendt et al., 2015). In Egypt, non- compliance rates increased to three quarters among schizophrenic patients (Kenfe et al., 2013).
where non - compliance with medications leads to increasing the rate of re-hospitalizations and visits to the emergency department.(Martin et al., 2018). Therefore, interventions that solely target symptoms are not sufficient, however a lot of holistic view is essential for which patients’ quality of life is a vital concern. Medication adherence is a key determinant of the success of pharmacotherapy in patients with schizophrenia and can have an impact on their quality of life. So, the present study will help psychiatric nurses and nursing researchers to advance their knowledge regarding quality of life and compliance to treatment in schizophrenic patients.
Aim of the study:
To assess quality of life and its relation with treatment compliance among schizophrenic patients. .
Research Setting:
The study was conducted at outpatient clinic including monthly treatment patients of the neuropsychiatric hospital at Assiut university hospital.
Sample:
Non probability (purposive) sample was used. Total sample included 110 patients (50 males & 60 females).
Tools: The tools that were used:-
Tool (1): Demographic and clinical data sheets (Appendix I):
This tool was developed by the researcher. It included age, sex, educational level, marital status, residence, occupation, duration of illness, number of admission and staying place of patients.
Tool (2): World Health Organization Quality of Life (WHOQOL) (Appendix II):
This tool was developed by World Health Organization, 1998. It contained 54 questions over 5 broad domains of QoL. Within which 18 facets are covered, to determine the quality of life. 5 main domains composed of: Physical health domain (7 items); psychological domain (4 items); social relationships domain(3 items); environment domain (3 items) and perceived quality of life domain (one item).
Tool (3): Medication Adherence Rating Scale (MARS) (Appendix III):
This tool was developed by Thompson et al., 2000. It contained 10 items self-reporting multidimensional instrument. It is describing three dimensions: medication adherence behavior (items1-4), attitude toward taking medication (items5-8) and negative side effects and attitude to psychotropic medication (items 9-10). Each question has” yes” or ”no” response. Total scores on the MARS ranged between 0 to 10, with a higher score indicating better medication adherence.